Mapping The Tumor 2.0

Mapping The Tumor 2.0

In an evolving oncology landscape, biomarker-driven treatment decisions are crucial. In 2021 there were over 17 updates to clinical guidelines for breast, prostate and ovarian cancer. Oncologists would have to read around 178 articles daily to keep up. With best practice always changing, time-poor HCP’s face information overload. As a result, 52% of community oncologists don’t use biomarker testing to inform treatment. Using a metaphor to highlight biomarker testing's importance, we simplified the scientific story to better educate HCPs and get patients the personalised treatment they need.


Awards


Yellow and Black D&AD Pencils

D&AD Awards 2027

Get to know the categories and enter your work.

Enter now

Details

Credits